Dose finding of ifosfamide administered with a chronic two-week continuous infusion

Oncology

Volumn 65, Issue SUPPL. 2, 2003, Pages 31-36

  Cartei, G ^a,d   Clocchiatti, L ^b   Sacco, C ^b   Pella, N ^b   Bearz, A ^c   Mantero, J ^a   Pastorelli, D ^a   Salmaso, F ^a   Zustovich, F ^a  

^a ULSS 16   (Italy)

^b Unit of Medical Oncology   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d General Oncology ULSS 16   (Italy)

Author keywords

Ifosfamide; Ifosfamide, two week continuous infusion

Indexed keywords

CHLORPHENTERMINE; CYCLOPHOSPHAMIDE; ELASTOMER; GRANISETRON; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; MICONAZOLE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN TOXICITY; BREAST CARCINOMA; CANCER REGRESSION; CATHETER; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DERMATITIS; DISEASE COURSE; DISEASE SEVERITY; DISTRESS SYNDROME; DOSE CALCULATION; DOSE RESPONSE; DRUG METABOLISM; ERYTHEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; LEUKOPENIA; LUNG CARCINOMA; LUNG TOXICITY; LYMPHOMA; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; SKIN EDEMA; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; STEADY STATE; STOMATITIS; TESTIS CARCINOMA; THROMBOCYTOPENIA; TOXICITY; UTERINE CERVIX CARCINOMA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; PROTECTIVE AGENTS;

EID: 0242288544     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073355     Document Type: Conference Paper

References (17)

1. Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E III: Influence of schedule on alkylating agent cytotoxicity in vivo and in vitro. Cancer Res 1989;49:5994-5998.
2. Lokich J, Anderson N: Infusional cancer chemotherapy: Historical evolution and future development at the Cancer Center of Boston. Cancer Invest 1996;13:202-226.
3. Frei E III, Antman KII: Combination chemotherapy, dose and schedule; in Holland JF, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaun RR (eds): Cancer Medicine, ed 4. Baltimore, Williams & Wilkins, 1997, vol 1, pp 817-837
4. Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J: Feasibility trial of high-dose 7-day continuous infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol 1997;40:273-276.
5. Boni C, Bisagni G, Manenti AL, Moretti G, Rondini E, Sassi M, Zedro A, Savoldi L: Ifosfamide bolus, followed by 5-day continuous infusion in extensive pretreated patients with advanced breast cancer. ASCO Proc 1997;16:162.
6. Michelotti A, Salvadori B, Donati S, Tognoni A, Tibaldi C, Conte PF: A dose-finding study of ifosfamide by 3-day continuous infusion in pretreated, advanced breast cancer patients. Tumori 1997;83:826-828.
7. Di Lauro V, Spazzapan S, Lombardi D et al: Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil. Tumori 2001;87:27-29.
8. Frustaci S, Comandone A, Bearz A, Boglione A, Buonadonna A, Stefanovski P, Bumma C: Efficacy and tolerability of an ifosfamide continuous infusion in soft tissue sarcoma patients. ASCO Proc 1998;17:518.
9. Walters RS, Holmes FA, Valero V, Esparzaq-Guerra L, Hortobagyi GN: Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol Cancer Clin Trials 1998;21:413-415.
10. Boddy AV, Cole M, Pearson DJ, Idle JR: The kinetics of auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995;36:53-60.
11. Kaplan LD, Moran T, Song L, Tuan B, Northfelt D: Continuous-infusion ifosfamide/mesna with daily etoposide for refractory HIV-associated non-Hodgkin's lymphoma. ASCO Proc 1998;17:48, abstr 185.
12. Wright JE, Elias A, Tretyakov O et al: High-dose ifosfamide, carboplatin and etoposide pharmacokinetics: Correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol 1995;36:345-351.
13. Lewis LD: Ifosfamide pharmacokinetics. Invest New Drugs 1991;9:305-311.
14. Lewis LD, Fitzgerald DL, Mohan P et al: The pharmacokinetics of ifosfamide given as short and long intravenous infusion in cancer patients. Br J Clin Pharmacol 1991;31:77-82.
15. Lewis LD, Fitzgerald DL, Harper PG et al: Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990;30:725-732.
16. Hryniuk WM: Average dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
17. Colvin M: The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982;9:1-7.